LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Heron Therapeutics Inc

Closed

SectorHealthcare

1.71 -7.07

Overview

Share price change

24h

Current

Min

1.7

Max

1.84

Key metrics

By Trading Economics

Income

-1M

2.6M

Sales

-1.9M

39M

EPS

0.013

Profit margin

6.773

Employees

122

EBITDA

-5M

3.7M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+244.02% upside

Dividends

By Dow Jones

Next Earnings

5 sie 2025

Market Stats

By TradingEconomics

Market Cap

-39M

313M

Previous open

8.78

Previous close

1.71

News Sentiment

By Acuity

36%

64%

117 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Heron Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 maj 2025, 23:40 UTC

Hot Stocks

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 maj 2025, 23:33 UTC

Major Market Movers

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 maj 2025, 23:25 UTC

Major Market Movers

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 maj 2025, 23:25 UTC

Earnings

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 maj 2025, 22:58 UTC

Earnings

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 maj 2025, 21:35 UTC

Earnings

Cisco Systems Names Patterson as CFO, Patel as President

14 maj 2025, 23:59 UTC

Market Talk

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 maj 2025, 23:49 UTC

Market Talk

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 maj 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

14 maj 2025, 23:48 UTC

Market Talk

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 maj 2025, 23:47 UTC

Market Talk

Gold Gains on Possible Technical Recovery -- Market Talk

14 maj 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 maj 2025, 23:10 UTC

Earnings

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 maj 2025, 23:07 UTC

Earnings

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 maj 2025, 23:00 UTC

Top News

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 maj 2025, 22:43 UTC

Earnings

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 maj 2025, 22:34 UTC

Earnings

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 maj 2025, 22:33 UTC

Earnings

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 maj 2025, 22:30 UTC

Earnings

Xero Did Not Declare a Dividend>XRO.AU

14 maj 2025, 22:30 UTC

Earnings

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 maj 2025, 22:30 UTC

Earnings

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 maj 2025, 22:30 UTC

Earnings

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 maj 2025, 22:28 UTC

Earnings

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 maj 2025, 22:28 UTC

Earnings

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 maj 2025, 22:27 UTC

Earnings

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 maj 2025, 22:27 UTC

Earnings

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 maj 2025, 22:23 UTC

Top News

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 maj 2025, 22:15 UTC

Earnings

Correction to Cisco Earnings Article -- WSJ

14 maj 2025, 21:48 UTC

Earnings

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 maj 2025, 21:37 UTC

Earnings

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Peer Comparison

Price change

Heron Therapeutics Inc Forecast

Price Target

By TipRanks

244.02% upside

12 Months Forecast

Average 6.33 USD  244.02%

High 9 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets forHeron Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

2.0001 / 2.42Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

117 / 382 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.